Replies to post #5133 on Amarin Corp Plc (AMRN)

[BaaBaa45]

Agreed, the generic would also need to be able to :

(i)source the supply of API at a time where Amarin has cornered the market;and
(ii) manufacture a bio equivalent product which will not be easy with a product like this.

Finally, the margins on this are not stellar compared to most drugs so the risk / reward may not stack up for a generic company.

..........and don't forget the statin/ vascepa combo product 3/4 years down the line.